HIGHTIDE THERAPEUTICS


Associated tags: Hypertriglyceridemia, PSC, Orphan drug, HighTide, Type 2 diabetes, NASH, Primary sclerosing cholangitis, T2DM, Fatty liver disease, Fast Track, Pharmaceutical industry, Patient, Biotechnology, Health, Pharmaceutical, Therapy, NAFLD, Clinical Trials, Primary biliary cholangitis, General Health, Institute of Liver and Biliary Sciences, Diabetes, Roy Taylor (scientist)

Locations: BAHRAIN, IRAN, IRAQ, JORDAN, KUWAIT, LEBANON, OMAN, PALESTINE, QATAR, SAUDI ARABIA, SYRIA, UNITED ARAB EMIRATES, YEMEN, MARYLAND, MIDDLE EAST, CHINA

HighTide Therapeutics Inc. is Invited to Present at the 7th Edition of the Future Investment Initiative (FII): The New Compass, in Riyadh, Saudi Arabia

Retrieved on: 
Friday, October 27, 2023

The rising burden of aging-related diseases has become an urgent global health challenge that requires immediate attention.

Key Points: 
  • The rising burden of aging-related diseases has become an urgent global health challenge that requires immediate attention.
  • Recent advances in anti-aging research and big data empower a more holistic approach to understanding and reversing human aging with evidence suggests that slowing down aging can substantially improve quality of life.
  • The FII Conference, hosted by the Future Investment Initiative (FII) Institute, has been held for seven consecutive years and has developed into one of the most important economic and investment forums in the Middle East.
  • This year's conference (FII7) was attended exclusively by FII Institute members, strategic partners, decision-makers, and international leaders, and is expected to draw 5,000 delegates attending sessions covering a wide variety of issues with global impact.

HighTide Therapeutics Announces First Patient Dosed in Phase 2b Clinical Study Evaluating HTD1801 in NASH (the CENTRICITY study)

Retrieved on: 
Wednesday, January 11, 2023

ROCKVILLE, MD and SHENZHEN, CHINA, Jan 11, 2023 - (ACN Newswire) - HighTide Therapeutics Inc. ("HighTide"), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the dosing of the first patient in a Phase 2b clinical study evaluating HTD1801 for the treatment of nonalcoholic steatohepatitis ("NASH").

Key Points: 
  • ROCKVILLE, MD and SHENZHEN, CHINA, Jan 11, 2023 - (ACN Newswire) - HighTide Therapeutics Inc. ("HighTide"), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the dosing of the first patient in a Phase 2b clinical study evaluating HTD1801 for the treatment of nonalcoholic steatohepatitis ("NASH").
  • This double-blind, randomized, placebo-controlled, multicentre Phase 2b study will evaluate the effect of HTD1801, 1250 mg twice daily (BID), compared to placebo BID on histologic improvement in adult subjects with NASH and liver fibrosis who also have type 2 diabetes mellitus ("T2DM") or pre-diabetes.
  • The study will enroll approximately 210 subjects with biopsy-confirmed NASH and evidence of stage 2 or stage 3 liver fibrosis.
  • "Nonalcoholic fatty liver disease ("NAFLD") is the most prevalent chronic liver disease worldwide with a global prevalence of 25.2% to 29.8%.

HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations

Retrieved on: 
Thursday, January 5, 2023

Proceeds of the financing will be used to advance multiple global development programs, including mid-to-late-stage clinical trials, and the commercialization and business development of the company's robust pipeline.

Key Points: 
  • Proceeds of the financing will be used to advance multiple global development programs, including mid-to-late-stage clinical trials, and the commercialization and business development of the company's robust pipeline.
  • "After completing a successful $60 million Series B+ round at the end of 2020, we are thrilled to have well-recognized investors participate in our C/C+ round.
  • "The Series C/C+ financing is a significant milestone for HighTide.
  • It will enable us to move aggressively to accelerate the clinical and commercial development of our innovative pipeline and external business collaborations."

HighTide Therapeutics Announces Presentations at The Liver Meeting® 2022

Retrieved on: 
Tuesday, October 25, 2022

HighTide Therapeutics, Inc. (HighTide), a clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced that two abstracts related to its HTD1801 development program will be presented at The Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), in Washington, DC (November 4 8, 2022).

Key Points: 
  • HighTide Therapeutics, Inc. (HighTide), a clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced that two abstracts related to its HTD1801 development program will be presented at The Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), in Washington, DC (November 4 8, 2022).
  • Emerging evidence supports the bidirectional relationship between intestinal microbiota and liver health.
  • Dysbiosis has been associated with the pathogensis and progression of multiple metabolic diseases and chronic inflammatory liver diseases, including nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC).
  • Presentations at the Liver Meeting 2022 include:
    We are very pleased to share these data, said Liping Liu, Ph.D., founder and Chief Executive Officer of HighTide.

HighTide Therapeutics Appoints Daniel Ripley as SVP Business Development

Retrieved on: 
Thursday, October 20, 2022

HighTide Therapeutics, Inc. (HighTide), a clinical-stage biopharmaceutical company developing multifunctional therapies for metabolic and digestive diseases, today announced the appointment of Daniel Ripley as Senior Vice President of Business Development.

Key Points: 
  • HighTide Therapeutics, Inc. (HighTide), a clinical-stage biopharmaceutical company developing multifunctional therapies for metabolic and digestive diseases, today announced the appointment of Daniel Ripley as Senior Vice President of Business Development.
  • Mr. Ripley has 25 years of experience in pharmaceutical business development.
  • Prior to Alpha Biopharma, Mr. Ripley served in several senior business development roles.
  • Prior to Conatus, Mr. Ripley was Senior Director, Business Development at Apricus Biosciences and Director, Business Development at Ionis Pharmaceuticals.

HighTide Therapeutics Announces Early Completion of Enrollment in Phase 2 Clinical Study Evaluating HTD1801 in Type 2 Diabetes Mellitus

Retrieved on: 
Tuesday, August 30, 2022

HighTide Therapeutics, Inc. (HighTide), a globally integrated clinical-stage biotechnology company focused on the development of innovative multi-functional therapeutics to address the complex pathophysiology of metabolic and digestive diseases, announced that enrollment was completed ahead of schedule in a Phase 2 study evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM) in China.

Key Points: 
  • HighTide Therapeutics, Inc. (HighTide), a globally integrated clinical-stage biotechnology company focused on the development of innovative multi-functional therapeutics to address the complex pathophysiology of metabolic and digestive diseases, announced that enrollment was completed ahead of schedule in a Phase 2 study evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM) in China.
  • The study enrolled 113 subjects, and the endpoints include the change in hemoglobin A1c (HbA1c) after 12 weeks of treatment as well as changes in biomarkers of NAFLD.
  • Previous Phase 2 study in adults with comorbid nonalcoholic steatohepatitis (NASH) and T2DM completed in the United States demonstrated overall clinical benefits across liver, lipid, glycemia, weight, metabolic, and cardiovascular health.
  • The multi-functional HTD1801 developed by HighTide aims to provide patients with broad clinical benefit across glycemia, liver, and cardiovascular health.

HighTide Therapeutics Announces First Patient Dosed in Phase 2 Clinical Study Evaluating HTD1801 in Type 2 Diabetes Mellitus

Retrieved on: 
Thursday, April 28, 2022

HighTide Therapeutics, Inc. (HighTide), a globally integrated clinical-stage biotechnology company developing drugs with multi-functional biological actions to address the complex pathophysiology of metabolic and digestive diseases, announced that the first patient was dosed in a phase 2 study evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM) in China.

Key Points: 
  • HighTide Therapeutics, Inc. (HighTide), a globally integrated clinical-stage biotechnology company developing drugs with multi-functional biological actions to address the complex pathophysiology of metabolic and digestive diseases, announced that the first patient was dosed in a phase 2 study evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM) in China.
  • T2DM and NAFLD remain the most common chronic diseases worldwide with rapidly increasing prevalence and incidence.
  • Given the strong association and overlapping pathophysiology, there is a sizable population of patients with comorbid T2DM and NAFLD.
  • The complex pathophysiology of T2DM and NAFLD requires the engagement of multiple mechanistic pathways to optimize pharmacological intervention.

HighTide Therapeutics Appoints Myleen Leoncavallo as SVP Regulatory Affairs and Quality Assurance

Retrieved on: 
Thursday, March 31, 2022

HighTide Therapeutics, Inc. (HighTide), a global, clinical-stage biopharmaceutical company leading the discovery and development of multi-functional drugs with synergistic effects to treat metabolic and digestive diseases, today announced the appointment of Myleen Leoncavallo as Senior Vice President of Regulatory Affairs and Quality Assurance.

Key Points: 
  • HighTide Therapeutics, Inc. (HighTide), a global, clinical-stage biopharmaceutical company leading the discovery and development of multi-functional drugs with synergistic effects to treat metabolic and digestive diseases, today announced the appointment of Myleen Leoncavallo as Senior Vice President of Regulatory Affairs and Quality Assurance.
  • Mrs. Leoncavallo will report to Dr. Leigh MacConell, Chief Development Officer of HighTide.
  • We are very pleased to welcome Myleen to HighTide, said Liping Liu, Ph.D., Chief Executive Officer of HighTide.
  • Prior to Mirum, Mrs. Leoncavallo served in several senior regulatory affairs roles, including positions at Ultragenyx Pharmaceuticals and BioMarin Pharmaceuticals, biopharmaceutical companies focused on rare diseases.